Payment overview · 2025
General Payments
$3,717.81
160 reported records · 31 companies
Healthcare provider profile · identity verified
Craig E Herrman, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · INDIANAPOLIS, IN · NPI 1750385332
Verified facts
What the public records show
CMS Open Payments records show Craig E Herrman, MD received $3,717.81 in general payments during 2025 across 160 reported records.
Vanda Pharmaceuticals Inc. accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Botox by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vumerity by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $869.67 | 23.4% | 24 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $605.17 | 16.3% | 31 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $324.09 | 8.7% | 27 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $263.18 | 7.1% | 11 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $262.54 | 7.1% | 9 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $131.64 | 3.5% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $118.62 | 3.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $96.37 | 2.6% | 5 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$85.95 | 2.3% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $78.85 | 2.1% | 3 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $73.45 | 2.0% | 3 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $72.48 | 1.9% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $71.14 | 1.9% | 3 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $69.91 | 1.9% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $66.55 | 1.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.17 | 1.3% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $47.58 | 1.3% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $45.78 | 1.2% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $44.26 | 1.2% | 2 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $43.57 | 1.2% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $41.43 | 1.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.46 | 1.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $36.74 | 1.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $30.96 | 0.8% | 2 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $25.60 | 0.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.06 | 0.7% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $23.15 | 0.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.67 | 0.6% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $20.58 | 0.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.42 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $13.77 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,717.81 | 160 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $869.67 | 24 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $466.56 | 23 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $324.09 | 27 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $263.18 | 11 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $262.54 | 9 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $232.99 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $197.76 | 9 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $138.61 | 8 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $118.62 | 5 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $118.54 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $114.56 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $96.37 | 5 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $73.45 | 3 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $72.48 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $71.14 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $66.55 | 2 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $49.25 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.17 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $49.17 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $47.58 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $44.26 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $41.43 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.46 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $36.74 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $30.96 | 2 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $25.60 | 1 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $23.15 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $22.67 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $19.30 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $18.59 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Baclofen | Baclofen | 112 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 22 |
| Gabapentin | Gabapentin | 69 | 28 |
| Kesimpta Pen | Ofatumumab | 59 | suppressed |
| Teriflunomide | Teriflunomide | 57 | suppressed |
| Levetiracetam | Levetiracetam | 51 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 11 |
| Zonisamide | Zonisamide | 47 | suppressed |
| Pregabalin | Pregabalin | 44 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | 11 |
| Aimovig Autoinjector | Erenumab-Aooe | 33 | suppressed |
| Dalfampridine Er | Dalfampridine | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 31 | suppressed |
| Prednisone | Prednisone | 31 | 20 |
| Topiramate | Topiramate | 25 | suppressed |
| Copaxone | Glatiramer Acetate | 23 | suppressed |
| Lacosamide | Lacosamide | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | suppressed |
| Modafinil | Modafinil | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 18 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 16 | suppressed |
| Botox | Onabotulinumtoxina | 16 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Acetazolamide Er | Acetazolamide | 13 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Vumerity | Diroximel Fumarate | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Lamotrigine Er | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,717.81 · 160 records | Vanda Pharmaceuticals Inc. | AVONEX, Apokyn, BOTOX, BRIUMVI, Bafiertam, CREXONT, Dysport, GOMEKLI, HYQVIA, Hizentra, INGREZZA, INSPIRE, KESIMPTA, KISUNLA, Leqembi, NUPLAZID, NURTEC ODT, Nayzilam, Ocrevus, Ocrevus Zunovo, PONVORY, QULIPTA, REXULTI, Symbravo, TYSABRI, Tascenso ODT, ULTOMIRIS, UPLIZNA, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, XYWAV, ZAVZPRET, ZEPOSIA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error